PROKIDNEY CORP.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
PROK$1.11-3.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows – Unaudited
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities | ||
| Net loss before noncontrolling interest | $(110,760) | $(114,852) |
| Adjustments to reconcile net loss before noncontrolling interest to net cash flows used in operating activities: | ||
| Depreciation and amortization | 4,738 | 3,858 |
| Equity-based compensation | 19,633 | 22,424 |
| Gain on marketable securities, net | (2,674) | (5,521) |
| Loss on lease disposition | 143 | – |
| Impairment of long-lived assets | 318 | 5,324 |
| Loss on disposal of equipment | 474 | 186 |
| Changes in operating assets and liabilities | ||
| Interest receivable | 1,210 | (3,728) |
| Prepaid and other assets | 7,795 | (8,489) |
| Accounts payable and accrued expenses | (8,075) | (114) |
| Income taxes payable | (406) | (1,268) |
| Net cash flows used in operating activities | (87,604) | (102,180) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (176,676) | (277,291) |
| Sales and maturities of marketable securities | 261,992 | 286,625 |
| Purchase of equipment and facility expansion | (9,444) | (4,000) |
| Net cash flows provided by investing activities | 75,872 | 5,334 |
| Cash flows from financing activities | ||
| Proceeds from sales of Class A common stock, net of offering costs | 7,102 | 144,325 |
| Payments on finance leases | (21) | (40) |
| Exercise of stock options | 854 | – |
| Net cash flows provided by financing activities | 7,935 | 144,285 |
| Net change in cash and cash equivalents | (3,797) | 47,439 |
| Cash, beginning of period | 99,120 | 60,649 |
| Cash, end of period | $95,323 | $108,088 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Right of use assets obtained in exchange for lease obligations | $2,005 | $2,621 |
| Exchange of Class B common stock | $5,252 | $15,357 |
| Impact of equity transactions and compensation on redeemable noncontrolling interest | $3,903 | $18,748 |
| Equipment and facility expansion included in accounts payable and accrued expenses | $835 | $910 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.